

Sandra Belij-Rammerstorfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6528965/publications.pdf>

Version: 2024-02-01

27
papers

13,326
citations

471061

17
h-index

525886

27
g-index

37
all docs

37
docs citations

37
times ranked

20739
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251. | 5.8 | 20 |
| 2 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111. | 6.3 | 3,887 |
| 3 | Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288. | 15.2 | 265 |
| 4 | T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278. | 15.2 | 473 |
| 5 | A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. <i>Med</i> , 2021, 2, 243-262.e8. | 2.2 | 62 |
| 6 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891. | 6.3 | 979 |
| 7 | The Integration of Human and Veterinary Studies for Better Understanding and Management of Crimean-Congo Haemorrhagic Fever. <i>Frontiers in Immunology</i> , 2021, 12, 629636. | 2.2 | 8 |
| 8 | Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021, 7, 594-602. | 5.3 | 118 |
| 9 | Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6. | 13.5 | 936 |
| 10 | Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7. | 13.5 | 442 |
| 11 | Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021, 12, 2893. | 5.8 | 104 |
| 12 | Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9. | 13.5 | 519 |
| 13 | ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915. | 2.0 | 15 |
| 14 | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13. | 13.5 | 630 |
| 15 | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990. | 6.3 | 214 |
| 16 | ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. <i>Nature</i> , 2020, 586, 578-582. | 13.7 | 840 |
| 17 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478. | 6.3 | 2,080 |
| 18 | Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993. | 6.3 | 1,196 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. <i>Npj Vaccines</i> , 2020, 5, 69. | 2.9 | 121 |
| 20 | The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. <i>Immunology</i> , 2020, 160, 223-232. | 2.0 | 86 |
| 21 | Oral warfarin affects some aspects of systemic immunomodulation with topical dinitrochlorobenzene (DNCB) in rats. <i>Cutaneous and Ocular Toxicology</i> , 2018, 37, 29-35. | 0.5 | 1 |
| 22 | The effect of infectious dose on humoral and cellular immune responses in <i>Chlamydomphila caviae</i> primary ocular infection. <i>PLoS ONE</i> , 2017, 12, e0180551. | 1.1 | 7 |
| 23 | Infectious dose and repeated infections are key factors influencing immune response characteristics in guinea pig ocular chlamydial infection. <i>Microbes and Infection</i> , 2016, 18, 254-262. | 1.0 | 8 |
| 24 | Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers. <i>PLoS ONE</i> , 2015, 10, e0144380. | 1.1 | 17 |
| 25 | Fatal COVID-19 Outcomes are Associated with an Antibody Response Targeting Epitopes Shared with Endemic Coronaviruses. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 3 |
| 26 | Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 2 |
| 27 | Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222). <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 23 |